• Embotics

  Led · Equity · Jun 2012

  Embotics provides a multi-cloud management platform for enterprise IT and managed service providers to automate and control virtualized and cloud environments. Its flagship product, Embotics vCommander, integrates into private, public, or hybrid infrastructures to enable delivery of IT as a service, intelligent automation, and IT governance and control. Led by CEO Michael L. Torto, the company serves enterprises and service providers. Embotics is based in Ottawa, Canada and recently opened U.S. headquarters in Boston. The company raised $12.1M in growth funding from Arrowroot Capital. It plans to use the proceeds to drive customer acquisition and expansion through increased investment in sales and marketing as well as product development. Embotics offers V‑Commander, a cloud management platform that automates private cloud provisioning, monitoring and optimization for mid-sized to large IT organizations. The company emphasizes continuous monitoring of virtual data centers to automate deployment and configuration of IT services. Embotics reported 300% growth in sales over the past year and 220% year‑on‑year growth in new customers, with clients including Bell, Deloitte, Cisco, CSC, the Dutch Ministry of Defence and MITRE. The company is headquartered in Ottawa, Canada and maintains offices in the U.S. and EMEA along with a growing global partner network. Embotics plans to use new funding to accelerate global sales and marketing and to hire additional software engineers to support product and customer growth. Total financing to date is $18 million. Embotics Corporation is a pioneer in virtualization and private cloud management that offers the V-Commander virtualization management system. The company describes V-Commander as an end-to-end, integrated, scalable platform that reduces data center complexity, decreases operational costs, and increases efficiency. Embotics recently launched V-Commander 3.7, which it says fulfills the company’s vision for an integrated platform to manage dynamic data centers. The company announced a new multi-million dollar round of financing from existing supporters to support growth. Proceeds will be used to expand engineering, sales and marketing across North America and Europe and to build the customer base for its virtualization management platform. Embotics is headquartered in Ottawa, Canada, has offices in the U.S., and a growing network of global partners.

• Azelon Pharmaceuticals

  Participated · Series A · Oct 2011

  Azelon Pharmaceuticals (formerly Zelos Therapeutics) is focused on developing novel formulations for the treatment of osteoporosis. Its lead program, ZT-034, is a nasal spray formulation of teriparatide (PTH1-34) intended as a convenient alternative to subcutaneous teriparatide (Forteo). ZT-034 showed a promising profile in initial human safety and pharmacology studies. The company is advancing ZT-034 into mid-stage clinical trials and is using the financing to support a Phase IIa pharmacodynamic study. Azelon recently restructured its management team, appointing Don Hayden as Executive Chairman and Joan Lau as president and CEO, while Brian MacDonald remains as a senior clinical advisor. The company is backed by venture investors including Prospect Venture Partners, Lighthouse Capital Partners and Covington Venture Fund.

No current team members are available.